LUMICEF is indicated for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies; treatment of generalized pustular psoriasis in adult patients who have had an inadequate response to conventional therapies; treatment of ankylosing spondylitis in adult patients who respond inadequately to conventional therapies; treatment of non-radiographic axial spondyloarthritis in adult patients who respond inadequately to conventional therapies.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
